Chris De Savi | BiopharmaTrend

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <title>Chris De Savi | BiopharmaTrend</title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <link rel="canonical" href="https://www.biopharmatrend.com/contributor/689/" />  <script async src="https://www.googletagmanager.com/gtag/js?id=G-YK7FCK71TD"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-YK7FCK71TD'); </script> <meta name="keywords" content="BiopharmaTrend, Chris De Savi, contributor, article" /> <meta name="description" content="As Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal …" />  <meta name="twitter:card" content="summary"> <meta name="twitter:title" content="Chris De Savi | BiopharmaTrend"> <meta name="twitter:description" content="As Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal …"> <meta name="twitter:image" content="https://www.biopharmatrend.com/files/user/496_1606676312831.jfif">  <meta property="og:type" content="article" /> <meta property="og:url" content="https://www.biopharmatrend.com/contributor/689/" /> <meta property="og:title" content="Chris De Savi | BiopharmaTrend" /> <meta property="og:description" content="As Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal …" /> <meta property="og:image" content="https://www.biopharmatrend.com/files/user/496_1606676312831.jfif"> <link rel="shortcut icon" href="/static/favicon.ab1145f4d518.ico" /> <link rel="stylesheet" type="text/css" href="/static/css/main.6dead4e2266d.css" /> </head> <body> <div id="main-preheader"> <div class="container block-preheader"> <div id="logo-top"> <a href="/"><b>BioPharmaTrend</b></a>  </div> <div class="burger-container"> <div class="burger-button-container"> <button type="button" class="burger-button" onclick="document.documentElement.classList.toggle('blockfix');this.parentElement.parentElement.classList.toggle('active');"> <div class="burger-line burger-line-1"></div> <div class="burger-line burger-line-2"></div> <div class="burger-line burger-line-3"></div> </button> </div>  <div id="main-search-menu"> <div class="top-search"> <form action="/search/" class="top-search-form"> <button type="submit" class="btn btn-default"><i class="glyphicon glyphicon-search"></i></button> <input type="text" name="q" value="" size="10" class="form-control form-control-inline" required="" placeholder="e.g. 'quantum tech' or 'stem cell'"> <input type="hidden" name="section" value="insights"> </form> <span class="top-search-switcher button" onclick="this.parentElement.classList.toggle('active')"> <span class="glyphicon glyphicon-search"></span> <span class="glyphicon glyphicon-remove"></span> </span> </div> <span class="top-search-switcher button"> <span class="glyphicon glyphicon-search"></span> </span> </div>  <nav id="main-menu"> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/news/"><b>Latest News</b></a> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">All Topics <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/topic/bioeconomy-society/">Bioeconomy & Society</a></li> <li><a class="top-menu-link" href="/topic/ai-digital/">AI & Digital</a></li> <li><a class="top-menu-link" href="/topic/startups/">Startups & Deals</a></li> <li><a class="top-menu-link" href="/topic/neurotech/">NeuroTech</a></li> <li><a class="top-menu-link" href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a class="top-menu-link" href="/topic/synbio/">Biotech</a></li> <li><a class="top-menu-link" href="/topic/tools-methods/">Tools & Methods</a></li> <li><a class="top-menu-link" href="/topic/healthtech/">HealthTech</a></li> <li><a class="top-menu-link" href="/topic/aging-research/">Aging & Longevity</a></li> <li><a class="top-menu-link" href="/topic/contract-research/">Contract Research</a></li> <div class="sub-menu-margin"></div>  <li><a class="top-menu-link" href="/section/latest/">Latest insights</a></li> <li><a class="top-menu-link" href="/premium-content/">Premium Content</a></li> <div class="sub-menu-margin" style="border-bottom: 1px solid limegreen;"></div> <li><a class="top-menu-link" href="/knowledge-center/">Knowledge Center</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/interviews/"><b>Interviews</b></a> </div>  <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">Companies <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu">  <li><a class="top-menu-link" href="/m/marketplace/">Company Directory</a></li> <li><a class="top-menu-link" href="/section/interviews/">Interviews with Thought Leaders</a></li> <li><a class="top-menu-link" href="/section/case-studies/">Sponsored Case Studies</a></li> <li><a class="top-menu-link" href="/m/editor-tool/">Create Company Profile</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">More <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/about/">About Us</a></li> <li><a class="top-menu-link" href="/about/team/">Our Team</a></li> <li><a class="top-menu-link" href="/about/advisory-board/">Advisory Board</a></li> <li><a class="top-menu-link" href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a class="top-menu-link" href="/events/">Partner Events Calendar</a></li> <li><a class="top-menu-link" href="/advertising-media-kit/">Advertise with Us</a></li> <li><a class="top-menu-link" href="/contributor/">Write for Us</a></li> </ul> </div> </div> </nav> </div> <div id="main-user-actions">  <div class="mobile-menu-item"> <a href="/membership/" class="button-subscribe top-menu-link">Subscribe</a> </div>  <div class="mobile-menu-item last"> <a href="#" class="mobile-menu-item-title" rel="nofollow" title="Login/Join" onclick="document.getElementById('login-popup').classList.toggle('hidden')"> <span class="glyphicon glyphicon-log-in"></span> <span class="mobile-hide-m">Login/Join</span> </a> </div> </div> </div> </div> <div id="main-preheader-margin"></div> <div id="sencondary-menu-block"> <div class="container clearfix"> <nav> <ul class="text-center"> <li><a href="/topic/ai-digital/">AI & Digital</a></li> <li><a href="/topic/startups/">Startups & Deals</a></li> <li><a href="/topic/neurotech/">NeuroTech</a></li> <li><a href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a href="/topic/synbio/">Biotech</a></li> <li><a href="/topic/tools-methods/">Tools & Methods</a></li> </ul> </nav> </div> </div>  <div id="main-content" class="container"> <main id="content" class="col-lg-9 col-md-8 col-sm-12 col-xs-12"> <article> <div class="row"> <div class="col-lg-2 col-md-3 col-sm-4 col-xs-12"> <img src="/files/user/496_1606676312831.jfif" class="img-circle" /> </div> <div class="col-lg-10 col-md-9 col-sm-8 col-xs-12"> <h1>Chris De Savi</h1> <p class="soc-buttons-grey"> <em>Vice President, Head of Drug Discovery at <strong>Kymera Therapeutics</strong></em>     <a href="http://linkedin.com/in/chrisdesavi" target="_blank" rel="nofollow"> <img src="/static/img/sm-in.fb9ea368635d.png" width="35" height="35" /></a>   </p> </div> </div> <br> <section class="clearfix"> <p>As Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal and computational chemistry, lead discovery (biochemistry, biophysics, structural biology), pre-clinical development (DMPK and Toxicology) and proteomics. His team contributes to all drug discovery phases at Kymera from project inception through to clinical candidate discovery and beyond. Prior to joining Kymera, Chris was head of chemistry at Blueprint Medicines, a precision medicine company specialized in kinase drug discovery and development. Chris has deep experience in leading discovery research groups and project teams in both global pharmaceutical and biotech companies. He has directly contributed to the invention of 9 clinical candidate drugs for oncology and inflammation disease – most recently BLU-945, a EGFR T790M/C797S triple mutant inhibitor for the treatment of lung cancer, AZD4573, a selective CDK9 inhibitor for the treatment of haematological malignancies and AZD9496, an oral, selective estrogen receptor degrader for the treatment of ER+ breast cancer. He co-discovered Barasertib (AZD1152), a selective Inhibitor of Aurora B kinase for the treatment of AML. He is an author of over 50 peer-reviewed publications and patents in the fields of medicinal chemistry and drug discovery and a PhD qualified chemist who has previously held academic positions at Queens’ College Cambridge and University of Cambridge, Cambridge, UK.</p> </section> <p style="line-height: 2.5;"><strong>Contributing Author </strong>   in <br> <a href="/topic/bioeconomy-society/posts/" class="btn btn-default">Bioeconomy & Society</a>   <a href="/topic/novel-therapeutics/posts/" class="btn btn-default">Novel Therapeutics</a>   </p> <div style="color:forestgreen; clear:both; margin-bottom: 1em;"> <p><strong>Disclaimer:</strong> All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.</p> <div style="border-bottom: 1px #999 solid;"></div> </div> </article> <section> <h3>Articles from Chris</h3> <article> <header> <h4><a href="/post/577-transformational-egfr-drug-discovery/">Transformational EGFR Drug Discovery</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>July 29, 2022</time>    <span class="glyphicon glyphicon-eye-open"></span> 2317<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-577.jpg" alt="Transformational EGFR Drug Discovery" /></div> <div class="post-abstract"> <p>Lung cancer accounted for 18% of deaths caused by cancer in 2020, making it the leading cause of cancer mortality globally.<br /> <br /> Non-small-cell lung cancer (NSCLC) accounts for the majority of these cases (80−85%), and mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are oncogenic drivers in a subset of this disease, adenocarcinoma.</p> </div> </article> <article> <header> <h4><a href="/post/517-tissue-selective-e3-ligase-based-degraders/">Tissue Selective E3 Ligase-based Degraders</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>May 31, 2022</time>    <span class="glyphicon glyphicon-eye-open"></span> 3593<br /> </footer> <div class="post-image"><img src="/files/blog/post-2022-05-31.png" alt="Tissue Selective E3 Ligase-based Degraders" /></div> <div class="post-abstract"> <p>The efficacy and selectivity of protein degrader drugs depend on their affinity to the target protein but also on the type of E3 ubiquitin ligase (E3) that is recruited to trigger proteasomal degradation. The arsenal of E3s that can be hijacked for targeted protein degradation (TPD) is still largely unexplored. Only about 2% of the more than 600 E3 ligases have been utilized to date. Exploiting additional E3 ligases that are selectively expressed in specific tissues or cell types, can broaden the applicability of TPD as a therapeutic modality.</p> </div> </article> <article> <header> <h4><a href="/post/473-anticipated-drug-approvals-2022/">Anticipated Drug Approvals 2022</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>Feb. 14, 2022</time>    <span class="glyphicon glyphicon-eye-open"></span> 2361<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-473.jpg" alt="Anticipated Drug Approvals 2022" /></div> <div class="post-abstract"> <p>Drug Discovery crystal ball gazing for the year ahead. And the hottest prospects are discussed below.<br /> <br /> We already have 5 CDER (FDA) approvals this year which are tantalizing new treatments for patients -</p> <ol> <li>Daridorexant (Quviviq), a selective dual antagonist of the orexin receptors OX1 and OX2 used for the treatment of insomnia. <a data-attribute-index="1" data-entity-hovercard-id="urn:li:fs_miniCompany:11051230" data-entity-type="MINI_COMPANY" href="https://www.linkedin.com/company/idorsia/" rel="nofollow">Idorsia Pharmaceuticals Ltd</a></li> <li>Abrocitinib (Cibinqo), a new JAK1 kinase inhibitor used for the treatment of atopic dermatitis. <a data-attribute-index="3" data-entity-hovercard-id="urn:li:fs_miniCompany:1185" data-entity-type="MINI_COMPANY" href="https://www.linkedin.com/company/pfizer/" rel="nofollow">Pfizer</a></li> <li>Tebentafusp (Kimmtrak), a bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat uveal melanoma (eye cancer). <a data-attribute-index="5" data-entity-hovercard-id="urn:li:fs_miniCompany:687450" data-entity-type="MINI_COMPANY" href="https://www.linkedin.com/company/immunocore/" rel="nofollow">Immunocore</a></li> <li>Faricimab (Vabysmo), a bispecific mAb, a VEGF, and Ang-2 inhibitor used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). <a data-attribute-index="7" data-entity-hovercard-id="urn:li:fs_miniCompany:2276" data-entity-type="MINI_COMPANY" href="https://www.linkedin.com/company/genentech/" rel="nofollow">Genentech</a></li> <li>Sutimlimab (Enjaymo), a mAb that is used to treat adults with cold agglutinin disease (CAD). <a data-attribute-index="9" data-entity-hovercard-id="urn:li:fs_miniCompany:1642" data-entity-type="MINI_COMPANY" href="https://www.linkedin.com/company/sanofi/" rel="nofollow">Sanofi</a></li> </ol> <p> </p> </div> </article> <article> <header> <h4><a href="/post/464-are-we-keeping-up-with-resistance/">Are We Keeping Up With Antimicrobial Resistance?</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>Jan. 24, 2022</time>    <span class="glyphicon glyphicon-eye-open"></span> 2139<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-464.jpg" alt="Are We Keeping Up With Antimicrobial Resistance?" /></div> <div class="post-abstract"> <p>Antimicrobial resistance (AMR) poses a major threat to human health.</p> <p>There were an estimated 4.95M deaths associated with bacterial AMR in 2019, including 1.27M deaths attributable to bacterial AMR.</p> <p>Lower respiratory infections accounted for more than 1.5M deaths associated with resistance in 2019, making it the most burdensome infectious syndrome. The six leading pathogens for deaths associated with bacterial antimicrobial resistance are Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.</p> </div> </article> <article> <header> <h4><a href="/post/447-breakthrough-medicine-2021/">Breakthrough Medicines 2021</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>Dec. 7, 2021</time>    <span class="glyphicon glyphicon-eye-open"></span> 2547<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-447.jpg" alt="Breakthrough Medicines 2021" /></div> <div class="post-abstract"> <p>It has been a momentous year of innovation for drug discovery while the world is still facing the deadliest pandemic in its history. Below is highlighted some of the most impactful breakthrough medicines. These approved or emerging treatments will have a profound positive and meaningful impact on human lives.<br /> <br /> Some of these medicines such as the COVID-19 vaccines and new oral anti-virals have been discovered at an unprecedented pace. The vaccines from both Pfizer BioNTech SE and Moderna also represent novel technologies to treat disease using messenger RNA (mRNA) to teach our cells how to make a protein that will trigger an immune response inside our bodies. A gargantuan global effort. Amazing innovation.</p> </div> </article> </section> </main> <aside id="main-sidebar" class="col-lg-3 col-md-4 col-sm-12 col-xs-12"> </aside> </div> <footer id="main-footer"><div class="container"> <div class="row"> <div class="col-12 col-sm-6 col-lg-3"> <h4 class="footer-logo"><span style="font-weight: 900">BiopharmaTrend</span>.com</h4> <div style="margin-bottom: 1.25em" class="footer-logo-slogan">Where Tech Meets Bio</div>  <div style="margin-bottom: 0.5em;"><a href="#main-footer" onclick="toggleMailingPopup(true)" style="color: lemonchiffon"> <img src="/static/img/sm-mail.a3210e82fe37.png" alt="mail" width="32" height="32" />  <b>Newsletter</b> </a></div> <div style="margin-bottom: 0.5em"><a href="https://www.linkedin.com/company/biopharmatrend-com/" rel="nofollow" target="_blank"> <img src="/static/img/sm-in.fb9ea368635d.png" alt="in" width="32" height="32" />  LinkedIn </a></div> <div style="margin-bottom: 0.5em"><a href="https://twitter.com/BiopharmaTrend" rel="nofollow" target="_blank"> <img src="/static/img/sm-x.9f3327271e1a.png" alt="x" width="32" height="32" />  X </a></div> <div style="margin-bottom: 0.5em"><a href="https://news.google.com/publications/CAAqBwgKMOaRugsw86zRAw?hl=en-US&gl=US&ceid=US:en" rel="nofollow" target="_blank"> <img src="/static/img/sm-gnews.ac9eb4674c84.png" alt="gnews" width="32" height="32" />  Google News </a></div> <div><a href="/rss/" rel="nofollow" target="_blank"> <img src="/static/img/sm-rss.bcd2cefd2eba.png" alt="rss" width="32" height="32" />  RSS Feed </a></div> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>About</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/about/">What we do</a></li> <li><a href="/editorial-calendar/">Editorial Calendar</a></li> <li><a href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a href="/terms-of-use/">Terms of Use</a></li> <li><a href="/privacy-policy/">Privacy Policy</a></li>  <li><a href="/about/disclaimer/">Disclaimer</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>We Offer</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/premium-content/"><b style="color: lemonchiffon">Premium Content</b></a></li> <li><a href="/m/marketplace/">BioTech Scout</a></li> <li><a href="/our-products/">Reports</a></li> <li><a href="/section/interviews/">Interviews</a></li> <li><a href="/events/">Partner Events</a></li> <li><a href="/section/case-studies/">Case Studies</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>Opportunities</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/membership/">Membership</a></li> <li><a href="/advertising-media-kit/">Advertise</a></li> <li><a href="/m/editor-tool/">Submit Company</a></li> <li><a href="/contributor/">Write for Us</a></li> <li><a href="/guest-blog/guidelines/">Author Guidelines</a></li> <li><a href="/a/contact/">Contact Us</a></li> </ul> </nav> </div> </div> <hr> <div class="text-right">© BPT Analytics LTD 2024</div> </div></footer> <div id="bpt-consent"><div class="container"> <div class="row"> <div class="col-12 col-md-6 col-lg-8"> We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our <a href="/cookies-policy/">cookies policy</a>. </div> <div class="col-12 col-md-6 col-lg-4 text-right"> <button class="btn btn-primary btn-sm" type="button" onclick="changeConsent('analytics')" style="white-space:unset">Agree</button> </div> </div> </div></div> <div id="login-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div class="popup-content" style="width: 25em;"> <form method="post" class="api-form" action="/a/login/?next=/contributor/689/"></form> </div> </div> <div id="subscription-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div id="subscription-popup-iframe" class="popup-content" style="width: 25em;"> </div> </div> <div id="scroll-top-pixel-anchor"></div> <button id="go-top" onclick="window.scrollTo({top: 20, left: 0, behavior: 'smooth'})">^</button> <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script> <script src="/static/js/main.df923d2272d3.js"></script> <script type="text/javascript"> if ( "IntersectionObserver" in window && "IntersectionObserverEntry" in window && "intersectionRatio" in window.IntersectionObserverEntry.prototype ) { let observer = new IntersectionObserver(entries => { if (entries[0].boundingClientRect.y < 0) { document.body.classList.add("scroll-top"); } else { document.body.classList.remove("scroll-top"); } }); observer.observe(document.getElementById("scroll-top-pixel-anchor")); } </script> </body> </html>

CINXE.COM

Chris De Savi | BiopharmaTrend